Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1996 1
2015 1
2016 1
2019 2
2020 1
2022 1
2024 0

Text availability

Article attribute

Article type

Publication date

Search Results

5 results

Results by year

Filters applied: . Clear all
Page 1
Salivary gland carcinoma (SGC) with perineural spread and/or positive resection margin - high locoregional control rates after photon (chemo) radiotherapy - experience from a monocentric analysis.
Haderlein M, Scherl C, Semrau S, Lettmaier S, Hecht M, Putz F, Iro H, Agaimy A, Fietkau R. Haderlein M, et al. Radiat Oncol. 2019 Apr 23;14(1):68. doi: 10.1186/s13014-019-1260-x. Radiat Oncol. 2019. PMID: 31014362 Free PMC article.
BACKGROUND: The aim was to evaluate the outcome, especially locoregional control of patients with locally advanced salivary gland carcinoma (SGC) with perineural spread (Pn1) and/or positive resection margins (R1/2) after postoperative photon (chemo) r …
BACKGROUND: The aim was to evaluate the outcome, especially locoregional control of patients with locally advanced salivary …
Evaluation of pembrolizumab monotherapy in patients with previously treated advanced salivary gland carcinoma in the phase 2 KEYNOTE-158 study.
Even C, Delord JP, Price KA, Nakagawa K, Oh DY, Burge M, Chung HC, Doi T, Fakih M, Takahashi S, Yao L, Jin F, Norwood K, Hansen AR. Even C, et al. Eur J Cancer. 2022 Aug;171:259-268. doi: 10.1016/j.ejca.2022.05.007. Epub 2022 Jun 28. Eur J Cancer. 2022. PMID: 35777186 Free article. Clinical Trial.
AIM: We evaluated pembrolizumab monotherapy in patients with advanced salivary gland carcinoma on the phase 2 KEYNOTE-158 study (NCT02628067). ...Immune-mediated adverse events occurred in 22.0% of patients (grade 3, 5.5%; grade 4-5, 0). CONCLUSIONS: A …
AIM: We evaluated pembrolizumab monotherapy in patients with advanced salivary gland carcinoma on the phase 2 KE …
Targeted therapy for advanced salivary gland carcinoma based on molecular profiling: results from MyPathway, a phase IIa multiple basket study.
Kurzrock R, Bowles DW, Kang H, Meric-Bernstam F, Hainsworth J, Spigel DR, Bose R, Burris H, Sweeney CJ, Beattie MS, Blotner S, Schulze K, Cuchelkar V, Swanton C. Kurzrock R, et al. Ann Oncol. 2020 Mar;31(3):412-421. doi: 10.1016/j.annonc.2019.11.018. Epub 2019 Dec 9. Ann Oncol. 2020. PMID: 32067683 Free PMC article. Clinical Trial.
The clinical benefit rate (defined by patients with objective responses or stable disease >4 months) was 67% (10/15), median progression-free survival (PFS) was 8.6 months, and median overall survival was 20.4 months. Stable disease was observed in the patient with a HE …
The clinical benefit rate (defined by patients with objective responses or stable disease >4 months) was 67% (10/15), median progression- …
Adjuvant chemoradiotherapy versus with radiotherapy alone for locally advanced salivary gland carcinoma among older patients.
Tanvetyanon T, Fisher K, Caudell J, Otto K, Padhya T, Trotti A. Tanvetyanon T, et al. Head Neck. 2016 Jun;38(6):863-70. doi: 10.1002/hed.24172. Epub 2015 Sep 4. Head Neck. 2016. PMID: 26340707
BACKGROUND: The majority of patients with locally advanced salivary gland carcinoma will die of the disease even after curative surgery. ...The median overall survival was 41.0 months with adjuvant radiotherapy and 24 months with CRT. Both multivariabl …
BACKGROUND: The majority of patients with locally advanced salivary gland carcinoma will die of the disease even …
Cisplatin, doxorubicin and cyclophosphamide in advanced salivary gland carcinoma. A phase II trial of 22 patients.
Licitra L, Cavina R, Grandi C, Palma SD, Guzzo M, Demicheli R, Molinari R. Licitra L, et al. Ann Oncol. 1996 Aug;7(6):640-2. doi: 10.1093/oxfordjournals.annonc.a010684. Ann Oncol. 1996. PMID: 8879381 Free article. Clinical Trial.
RESULTS: Of 22 patients, six achieved a partial response (27%, 95% CI: 11%-50%): no complete response was observed. Response duration ranged between 3 and 13 months (median seven months). ...
RESULTS: Of 22 patients, six achieved a partial response (27%, 95% CI: 11%-50%): no complete response was observed. Response duration …